TC

20/08/2019 15:34

{I-bank focus}Huatai trims CSPC Pharma (01093) to HK$18.2

[ET Net News Agency, 20 August 2019] Huatai Research lowered its target price for CSPC
Pharmaceutical Group (CSPC)(01093) to HK$18.2 from HK$18.3 and maintained its "buy"
rating.
Considering the accelerating growth of the oncology franchise, the research house raised
its 2019/20/21 EPS forecasts slightly by 0.4%/0.8%/1.6% to RMB0.64/0.80/0.95.
NBP realized 36% in sales in 1H, and Huatai expects sales growth of over 30% in 2019,
given (1) enlarged salesforce headcount; (2) increased hospital coverage; and (3) low
potential to enter monitored drug catalogue.
Huatai also projected R&D expense to reach RMB2bn in 2019 and 10 drugs may enter pivotal
clinical trials by 2020. (KL)

etnet財經‧生活App   財智‧健康‧品味生活     【立即下載】  iOS版 / Android版
人氣文章
財經新聞
評論
專題
產品簡介

【etnet Bonus賞你】好好社企 中秋精選月餅禮盒

【etnet Bonus賞你】領展TKO Gateway便攜式香薰機

【etnet Bonus賞你】荃灣千色匯及元朗千色匯 x 韓國紙雕插畫藝術家Soo Min Kim 消暑手搖沙冰杯+簡約家用收納箱